NCT06185309

Brief Summary

  1. 1.Evaluate psychiatric symptoms in patients with thyroid dysfunction.
  2. 2.Investigate effect of treatment on psychiatric symptoms after 2 months.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
85

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2024

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 5, 2023

Completed
24 days until next milestone

First Posted

Study publicly available on registry

December 29, 2023

Completed
3 days until next milestone

Study Start

First participant enrolled

January 1, 2024

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2025

Completed
Last Updated

December 29, 2023

Status Verified

December 1, 2023

Enrollment Period

1 year

First QC Date

December 5, 2023

Last Update Submit

December 14, 2023

Conditions

AnxietyDepressionThyroid Dysfunction

Outcome Measures

Primary Outcomes (1)

  • The effect of thyroid treatment on psychiatric symptoms

    Investigate the effect of thyroid treatment on psychiatric symptoms associated with thyroid dysfunction.

    2 months

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients newly diagnosed as having thyroid dysfunction.

You may qualify if:

  • Patients newly diagnosed as having thyroid dysfunction.

You may not qualify if:

  • Patients with other endocrinological disorders or significant medical or neurological diseases.
  • Alcohol or substance abuse

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (2)

  • Aslan S, Ersoy R, Kuruoglu AC, Karakoc A, Cakir N. Psychiatric symptoms and diagnoses in thyroid disorders: a cross-sectional study. Int J Psychiatry Clin Pract. 2005;9(3):187-92. doi: 10.1080/13651500510029129.

    PMID: 24937789RESULT

  • Gulseren S, Gulseren L, Hekimsoy Z, Cetinay P, Ozen C, Tokatlioglu B. Depression, anxiety, health-related quality of life, and disability in patients with overt and subclinical thyroid dysfunction. Arch Med Res. 2006 Jan;37(1):133-9. doi: 10.1016/j.arcmed.2005.05.008.

    PMID: 16314199RESULT

Related Links

MeSH Terms

Conditions

Anxiety DisordersDepression

Condition Hierarchy (Ancestors)

Mental DisordersBehavioral SymptomsBehavior

Study Officials

  • Romany Hosny Gabra Henein, professor

    Assiut University

    STUDY DIRECTOR

  • Khaled Ahmed Mohamed, Professor

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

Ahmed EamdElden Mohamed Abdelhafez, MBCCH

CONTACT

+201000316881ahmed.15235502@med.aun.edu.eg

Kerolos Hana, MBCCH

CONTACT

+201140623624a7mdemad91@gmail.com

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
2 Months
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Doctor resident

Study Record Dates

First Submitted

December 5, 2023

First Posted

December 29, 2023

Study Start

January 1, 2024

Primary Completion

January 1, 2025

Study Completion

February 1, 2025

Last Updated

December 29, 2023

Record last verified: 2023-12